Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Assets (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Assets for 12 consecutive years, with $166.4 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 25.74% year-over-year to $166.4 million; the TTM value through Mar 2026 reached $784.4 million, down 12.02%, while the annual FY2025 figure was $167.1 million, 23.47% down from the prior year.
  • Non-Current Assets hit $166.4 million in Q1 2026 for Cartesian Therapeutics, roughly flat from $167.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $226.2 million in Q3 2024 and bottomed at $15.5 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $130.7 million, with a median of $167.1 million recorded in 2025.
  • Year-over-year, Non-Current Assets skyrocketed 1299.2% in 2024 and then dropped 25.74% in 2026.
  • Cartesian Therapeutics' Non-Current Assets stood at $17.7 million in 2022, then surged by 1107.58% to $214.3 million in 2023, then rose by 1.9% to $218.4 million in 2024, then decreased by 23.47% to $167.1 million in 2025, then fell by 0.47% to $166.4 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $166.4 million, $167.1 million, and $225.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.